{"id":47589,"date":"2022-08-23T22:01:47","date_gmt":"2022-08-23T20:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/proprietary-state-of-specialty-spend-and-trend-report-released-by-pharmaceutical-strategies-group\/"},"modified":"2022-08-23T22:01:47","modified_gmt":"2022-08-23T20:01:47","slug":"proprietary-state-of-specialty-spend-and-trend-report-released-by-pharmaceutical-strategies-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/proprietary-state-of-specialty-spend-and-trend-report-released-by-pharmaceutical-strategies-group\/","title":{"rendered":"Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group"},"content":{"rendered":"
\n

\nSpecialty trend maintains double-digit growth as more specialty drugs <\/i>enter market despite growing prevalence of biosimilars<\/i>\n<\/p>\n

DALLAS–(BUSINESS WIRE)–#analytics<\/a>–Pharmaceutical Strategies Group (PSG), an EPIC company, has released its highly anticipated Artemetrx<\/a>\u00ae<\/sup> State of Specialty Spend and Trend Report. The sixth-annual report uses integrated pharmacy and medical claims data to formulate a holistic view of specialty spend and trend. Since its inception in 2017, it has served as the only comprehensive analysis of specialty drug spending, powered by the industry\u2019s leading integrated dataset through Artemetrx.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cSpecialty trend returned to a pre-pandemic level in 2021, rebounding to 14.2%,\u201d said Michael Lonergan<\/a>, RPh, President of PSG. \u201cHowever, it is encouraging to see competition from biosimilars impact cost. We saw an overall increase in utilization, from 12.4% in 2020 to 22.5% in 2021 and expect more meaningful impact as biosimilars for Humira enter the market next year.\u201d\n<\/p>\n

\nAs with 2020, claim utilization continues to drive trend. In fact, 9.4% of the 14.2% 2021 trend was due to increased claim utilization and 4.4% due to changes in cost per claim. Thus, while very high-cost therapies capture the spotlight, utilization is driving the specialty trend. We anticipate that as new costly therapies for higher prevalence diseases such as migraines and asthma are introduced, the double-digit trend will likely continue.\n<\/p>\n

\n\u201cWhile the definition of what comprises specialty drugs has shifted since the inception of this report six years ago, the importance of proactive specialty drug program management has not changed,\u201d said Renee Rayburg<\/a>, RPh, Vice President of Specialty Clinical Consulting. \u201cOur data supplies the needed precision to track trend drivers and keep pace with the rapidly changing market complexities, allowing for the construction of appropriate plan strategies,\u201d commented Rayburg. \u201cAccess to integrated data creates the ability to align PBM and health plan strategies to achieve the maximum financial benefit.\u201d\n<\/p>\n

\n\u201cThe Artemetrx Specialty Spend and Trend report is an important tool to aide in the assessment and design of specialty pharmacy strategy,\u201d noted Timothy Carroll, PharmD \u2013 VP, Business Development and Analytics, Reliance Rx<\/a>. \u201cIt becomes more essential as new therapies, generics and biosimilars are introduced and paradigms are continually shifting.\u201d\n<\/p>\n

\nKey takeaways from the Spend and Trend Report include:<\/b>\n<\/p>\n